Loading...
•
Dec 31, 2023
Soleno Therapeutics Q4 2023 Earnings Report
Soleno Therapeutics reported financial results for Q4 2023 and provided a corporate update.
Key Takeaways
Soleno Therapeutics reported a net loss of $11.3 million for the fourth quarter of 2023. The company's research and development expenses were $8.7 million, and general and administrative expenses were $4.1 million. As of December 31, 2023, Soleno had cash and cash equivalents of approximately $169.7 million.
Announced positive statistically significant top-line data from the randomized withdrawal period of Study C602.
Planned NDA submission for DCCR in PWS remains on track for mid-2024.
Closed on gross proceeds of approximately $129 million from an underwritten public offering.
Strengthened leadership team with appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources.
Forward Guidance
Soleno remains focused on preparing an NDA submission for DCCR in PWS mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...